Home › Compare › ARTH vs XYLD

ARTH vs XYLD: Dividend Comparison 2026

ARTH yields 2000000.00% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARTH wins by $4.879226400974806e+39M in total portfolio value
10 years
ARTH
ARTH
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full ARTH calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — ARTH vs XYLD

📍 ARTH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARTHXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARTH + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ARTH pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARTH
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, ARTH beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARTH + XYLD for your $10,000?

ARTH: 50%XYLD: 50%
100% XYLD50/50100% ARTH
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARTH right now

ARTH
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-103.9
Piotroski
3/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARTH buys
0
XYLD buys
0
No recent congressional trades found for ARTH or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARTHXYLD
Forward yield2000000.00% ✓10.98%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.879226400974806e+39M$25.3K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$3,219.02
Total dividends collected$4.879195005460081e+39M$19.6K ✓
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ARTH vs XYLD ($10,000, DRIP)

YearARTH PortfolioARTH Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,818$1,098.39+$200.00M → ARTH
2$3,738,731,768,458$3,738,517,757,009.35$11,738$1,222.51+$3738731.76M → ARTH
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,774$1,364.64+$65315062866.92M → ARTH
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,944$1,527.86+$1066400830062625.00M → ARTH
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$15,270$1,715.87+$16272182796453826560.00M → ARTH
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$16,775$1,933.09+$2.3205424011366188e+23M → ARTH
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$18,490$2,184.87+$3.0927990661046884e+27M → ARTH
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$20,450$2,477.63+$3.8524105697352695e+31M → ARTH
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$22,697$2,819.19+$4.484688260147987e+35M → ARTH
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$25,280$3,219.02+$4.879226400974806e+39M → ARTH

ARTH vs XYLD: Complete Analysis 2026

ARTH — Stock

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

Full ARTH Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this ARTH vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARTH vs SCHDARTH vs JEPIARTH vs OARTH vs KOARTH vs MAINARTH vs QYLDARTH vs JEPQARTH vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.